Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience

References

• Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–128. doi:10.1016/j.gene.2019.02.076
   PubMed Web of Science ®Google Scholar
• Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464. doi:10.3390/ijms22073464
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. doi:10.1056/NEJMoa1813904
   PubMed Web of Science ®Google Scholar
• Ballotari P, Vicentini M, Manicardi V, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer. 2017;17(1):1–8. doi:10.1186/s12885-017-3696-4
   PubMedGoogle Scholar
• Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841. doi:10.1056/NEJMoa1008862
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013;24(10):2506–2514. doi:10.1093/annonc/mdt224
   PubMed Web of Science ®Google Scholar
• Lee J-S, Tocheny CE, Shaw LM. The insulin-like growth factor signaling pathway in breast cancer: an elusive therapeutic target. Life. 2022;12(12):1992. doi:10.3390/life12121992
   PubMedGoogle Scholar
• Werner H, LeRoith D. Hallmarks of cancer: the insulin-like growth factors perspective. Front Oncol. 2022;12:1055589. doi:10.3389/fonc.2022.1055589
   PubMed Web of Science ®Google Scholar
• Farabaugh SM, Boone DN, Lee AV. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol. 2015;6(APR):1–12. doi:10.3389/fendo.2015.00059
   PubMedGoogle Scholar
• Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008;68(24):10238–10246. doi:10.1158/0008-5472.CAN-08-2755
   PubMed Web of Science ®Google Scholar
• Sarfstein R, Pasmanik-Chor M, Yeheskel A, et al. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem. 2012;287(4):2766–2776. doi:10.1074/jbc.M111.281782
   PubMed Web of Science ®Google Scholar
• Guvakova MA, Adams JC, Boettiger D. Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci. 2002;115(Pt 21):4149–4165. doi:10.1242/jcs.00104
   PubMed Web of Science ®Google Scholar
• Matà R, Palladino C, Nicolosi ML, et al. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget. 2016;7(7):7683–7700. doi:10.18632/oncotarget.6524
   PubMedGoogle Scholar
• Chang WW, Lin RJ, Yu J, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res. 2013;15(3):R39. doi:10.1186/bcr3423
   PubMed Web of Science ®Google Scholar
• Hopkins BD, Pauli C, Xing D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499–503. doi:10.1038/s41586-018-0343-4
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24(4):710–719. doi:10.2337/diacare.24.4.710
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes Vasc Dis Res. 2019;16(2):133–143. doi:10.1177/1479164118825376
   PubMed Web of Science ®Google Scholar
• Bazelier MT, de Vries F, Vestergaard P, et al. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol. 2013;4(FEB):1–9.
   PubMedGoogle Scholar
• Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized Phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–1010. doi:10.1016/j.annonc.2020.05.001
   PubMed Web of Science ®Google Scholar
• Carrillo M, Rodriguez RM, Walsh CL, Mcgarvey M. Alpelisib-induced diabetic ketoacidosis: a case report and review of literature. AACE Clin Case Rep. 2021;7(2):127–131. doi:10.1016/j.aace.2020.11.028
   PubMedGoogle Scholar
• Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther. 2017;8(4):705–726. doi:10.1007/s13300-017-0273-4
   PubMed Web of Science ®Google Scholar
• Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a Phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489–498. doi:10.1016/S1470-2045(21)00034-6
   PubMed Web of Science ®Google Scholar
• Mu X, Xiang Z, Xu Y, et al. Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes. Cell Mol Immunol. 2022;19(8):944–956. doi:10.1038/s41423-022-00894-x
   PubMed Web of Science ®Google Scholar
• Sai J, Owens P, Novitskiy SV, et al. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses. Clin Cancer Res. 2017;23(13):3371–3384. doi:10.1158/1078-0432.CCR-16-2142
   PubMed Web of Science ®Google Scholar
• Taghizadeh-Hesary F, Akbari H, Bahadori M, Behnam B. Targeted anti-mitochondrial therapy: the future of oncology. Genes. 2022;13(10):1728. doi:10.3390/genes13101728
   PubMed Web of Science ®Google Scholar
• Gao M, Wang J, Wang W, Liu J, Wong C-W. Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor γ coactivator-1β expression. Br J Pharmacol. 2011;162(4):1000–1008. doi:10.1111/j.1476-5381.2010.01105.x
   PubMed Web of Science ®Google Scholar